NCT00647621View on ClinicalTrials.gov

Steady-State Study of Extended Phenytoin Sodium Capsules 100 mg and Dilantin® Kapseals® 100 mg

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

December 31, 2005

Study Completion Date

December 31, 2005

Conditions
Healthy
Interventions
DRUG

Extended Phenytoin Sodium Capsules 100 mg

3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16

DRUG

Dilantin® Kapseals® 100 mg

3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16

Trial Locations (1)

58104

PRACS Institute, Ltd., Fargo

Sponsors
All Listed Sponsors
lead

Mylan Pharmaceuticals Inc

INDUSTRY

NCT00647621 - Steady-State Study of Extended Phenytoin Sodium Capsules 100 mg and Dilantin® Kapseals® 100 mg | Biotech Hunter | Biotech Hunter